Detection of Aneuploidy in Cell Free DNA to Improve the Sensitivity of Diagnostic Peritoneal Lavage in Gastric Cancer
Recruiting
Observational Study
Gastric Cancer
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
Healthy Volunteers Welcome
You do not need to have the condition being studied to take part.
No Study Drug
Researchers observe your health over time — no experimental treatment is given.
At a Glance
- Age
- 18 and older
- Sex
- Any
- Study type
- Observational
- Participants needed
- 63 (estimated)
- Sponsor
- Erasmus Medical Center · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
Aneuploidy may be used as a more sensitive diagnostic tool to detect peritoneal metastasis compared to conventional cytology and imaging techniques. Our aim is to establish whether aneuploidy as detected in cfDNA (as a measure for ctDNA) in PLF of patients with GC may hold value as an additional staging and tumor evaluation method in GC patients.
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Gastric cancer patients:
Inclusion Criteria:
* Age ≥18 years old;
* Written informed consent according to the ICH-GCP and national/local regula-tions.
Exclusion Criteria:
\- Language difficulty, dementia or altered mental status prohibiting the under-standing and giving of informed consent.
non…
Contacts